Sex: F
Vaccine: COVID19, UNK
Symptoms: Blood test, Immunodeficiency, Neutropenia
Clinical narrative: no immune system because of Ibrance; blood work following day after vaccine was neutropenic; This spontaneous case was reported by a patient and describes the occurrence of IMMUNODEFICIENCY (no immune system because of Ibrance) and NEUTROPENIA (blood work following day after vaccine was neutropenic) in a female patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.    Co-suspect product included non-company product PALBOCICLIB (IBRANCE) for Breast cancer metastatic.    Concurrent medical conditions included Breast cancer metastatic and Hypothyroidism. Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID) for Hypothyroidism.   On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 100 milligram and PALBOCICLIB (IBRANCE) (unknown route) 125 milligram. On an unknown date, PALBOCICLIB (IBRANCE) (unknown route) dosage was changed to 100 milligram and PALBOCICLIB (IBRANCE) (unknown route) dosage was changed to 75 milligram once a day. On an unknown date, the patient experienced IMMUNODEFICIENCY (no immune system because of Ibrance) (seriousness criterion medically significant) and NEUTROPENIA (blood work following day after vaccine was neutropenic) (seriousness criterion medically significant). At the time of the report, IMMUNODEFICIENCY (no immune system because of Ibrance) outcome was unknown and NEUTROPENIA (blood work following day after vaccine was neutropenic) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood test: Not normal/neutropenic, Blood levels were much more normal, Neutropenic following day after vaccine and Normal.     The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter considered IMMUNODEFICIENCY (no immune system because of Ibrance) to be not related. No further causality assessment was provided for NEUTROPENIA (blood work following day after vaccine was neutropenic).    The patient had no immune system because of Ibrance. Blood was measured every four weeks and sometimes had to measure blood before four weeks and was not normal. Patient had to avoid certain activity. Patient had been neutropenic four or five times but was able to manage by lowering dose of Ibrance from 125 milligram to 100 milligram and then was taking 75 milligrams. It seemed to be better. Blood levels were much more normal. Patient had to have Moderna covid vaccine the day before doing blood work and the blood work following day after vaccine was neutropenic. Patient delayed the start of Ibrance. Patient used to start Ibrance every 21 days but had to delay a week before starting Ibrance to see if levels came back up. Blood levels were measured again after 5 days and were normal. Patient was given 100 mg of Moderna Covid-19 vaccine versus the 50 mg average person was given. Patient was able to start Ibrance.   No treatment medications were reported.  Company Comment : This is a spontaneous case concerning  a female patient of unknown age, with Concurrent medical conditions included Breast cancer metastatic and Hypothyroidism, who experienced the unexpected serious (medically significant) events of Immunodeficiency, Neutropenia. The exact date of administration of unspecified dose of mRNA-1273 and onset of the events was not specified, hence latency could not be assessed. Patient has no significant lab results. The patient had no immune system because of Ibrance. Blood was measured every four weeks and sometimes had to measure blood before four weeks and was not normal. Patient had to avoid certain activity. Patient had been neutropenic four or five times but was able to manage by lowering dose of Ibrance from 125 milligram to 100 milligram and then was taking 75 milligrams. It seemed to be better. Blood levels were much more normal. Patient had to have Moderna covid vaccine the day before doing blood work and the blood work following day after vaccine was neutropenic. Patient delayed the start of Ibrance. Patient used to start Ibrance every 21 days but had to delay a week before starting Ibrance to see if levels came back up. Blood levels were measured again after 5 days and were normal. Patient was able to start Ibrance. No treatment received were reported. The Concurrent medical conditions included Breast cancer metastatic and Hypothyroidism remains a confounder. The benefit-risk relationship of mRNA-1273 Vaccine, is not affected by this report.; Reporter's Comments: ,; Sender's Comments: This is a spontaneous case concerning  a female patient of unknown age, with Concurrent medical conditions included Breast cancer metastatic and Hypothyroidism, who experienced the unexpected serious (medically significant) events of Immunodeficiency, Neutropenia. The exact date of administration of unspecified dose of mRNA-1273 and onset of the events was not specified, hence latency could not be assessed. Patient has no significant lab results. The patient had no immune system because of Ibrance. Blood was measured every four weeks and sometimes had to measure blood before four weeks and was not normal. Patient had to avoid certain activity. Patient had been neutropenic four or five times but was able to manage by lowering dose of Ibrance from 125 milligram to 100 milligram and then was taking 75 milligrams. It seemed to be better. Blood levels were much more normal. Patient had to have Moderna covid vaccine the day before doing blood work and the blood work following day after vaccine was neutropenic. Patient delayed the start of Ibrance. Patient used to start Ibrance every 21 days but had to delay a week before starting Ibrance to see if levels came back up. Blood levels were measured again after 5 days and were normal. Patient was able to start Ibrance. No treatment received were reported. The Concurrent medical conditions included Breast cancer metastatic and Hypothyroidism remains a confounder. The benefit-risk relationship of mRNA-1273 Vaccine, is not affected by this report.